The antihelmintic medication niclosamide displays its anticancer effects by inhibiting the S100A4 promoter activity and by inhibiting the Wnt/β-catenin signaling pathway, which is a major regulatory pathway for the initiation of cancer, tumor growth, cell differentiation, and metastasis [15, 16]. This evidence concerns the gene S100A4 and cancer.